biote Corp. (BTMD) Tops Q4 EPS by 11c, Revenue In Line; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biote Reports Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024 4:05 PM EDTGrew practitioner network to over 7,100 from 6,400 in 2022
Launched BioteRx, our new hormone and therapeutic wellness offerings
Enhancing shareholder value with agreement to repurchase 18.4M founders shares in addition to a separate $20M share repurchase program
Reaffirms 2024 financial guidance, with an acceleration in second half growth
